| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue from collaboration agreements | -18,779 | NaN | 24,931 | NaN |
| research and development | 24,606 | NaN | NaN | NaN |
| General and administrative | 9,331 | NaN | NaN | NaN |
| Total operating expenses | -83,071 | NaN | 117,008 | NaN |
| Non-operating income | -4,913 | NaN | 7,569 | NaN |
| Net loss | -25,129 | -20,486 | -32,166 | -52,342 |
| Stock-based compensation expense | 2,671 | 4,007 | 4,593 | 10,499 |
| Impairment loss on right-of-use asset | NaN | 10,733 | NaN | NaN |
| Impairment of long-lived assets | NaN | NaN | 10,733 | NaN |
| Depreciation and amortization | NaN | 1,959 | NaN | NaN |
| Depreciation and amortization expense | -1,127 | NaN | 460 | 1,071 |
| Reduction in carrying amount of right-of-use asset | 1,441 | 1,429 | 1,688 | 3,317 |
| Net accretion of discounts on marketable securities | 1,089 | 863 | 515 | 1,364 |
| Other | 30 | 21 | 30 | 48 |
| Accounts receivable | 482 | -4,141 | 4,341 | -901 |
| Prepaid expenses and other current and long-term assets | -122 | 2,258 | 572 | -3,974 |
| Accounts payable | -85 | -472 | -885 | 889 |
| Accrued expenses and other current liabilities | -3,522 | 2,069 | -2,015 | -6,103 |
| Operating lease liability | -1,536 | -1,480 | -1,461 | -2,833 |
| Deferred revenue | -2,769 | -8,681 | -6,756 | -3,399 |
| Net cash used in operating activities | -29,944 | -22,145 | -31,207 | -45,342 |
| Proceeds from maturities of marketable securities | 57,029 | 52,349 | 51,180 | 115,551 |
| Purchases of marketable securities | 40,812 | 133,071 | 46,683 | 47,320 |
| Purchases of property and equipment, net | 64 | 11 | 411 | 185 |
| Net cash provided by investing activities | 16,153 | -80,733 | 4,086 | 68,046 |
| Proceeds from issuance of common stock-Underwritten Offering | NaN | 116,870 | NaN | NaN |
| Proceeds from issuance of common stock-At The Market | NaN | NaN | 7,526 | 0 |
| Proceeds from issuance of common stock-At The Market Equity Program | NaN | 9,341 | NaN | NaN |
| Proceeds from issuance of common stock-Stock Purchase Agreement | NaN | NaN | 0 | 0 |
| Proceeds from issuance of common stock-Betta Pharma Stock Purchase Agreement | NaN | 0 | NaN | NaN |
| Proceeds from exercise of stock options | 605 | 0 | 107 | 0 |
| Proceeds from exercise of warrants | 1 | NaN | NaN | NaN |
| Payments for repurchase of common stock for tax withholding | 200 | 14 | 24 | 155 |
| Other | 56 | 1 | 164 | 109 |
| Net cash provided by (used in) financing activities | 462 | 118,672 | 7,773 | -46 |
| Net change in cash, cash equivalents and restricted cash | -13,329 | 15,794 | -19,348 | 22,658 |
| Cash, cash equivalents and restricted cash at beginning of period | 78,046 | 62,252 | 58,942 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 64,717 | 78,046 | 62,252 | NaN |
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)